Saccharomyces boulardii 用于 Clostridioides difficile Infection (CDI)
BMeta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.
Key Study Findings
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: Pediatric population
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
效果: None
None
研究人群: Patients with C. difficile infection
Review
520 weeks
Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Review
Clostridium difficile Colitis Prevention and Treatment.
Dose: None
vs: None
Outcome: Diarrhea outcomes
效果: None
None
研究人群: None
Systematic Review
n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None
vs: None
Outcome: Diarrhea outcomes
效果: None
None
研究人群: None
Review
Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
Dose: None
vs: None
Outcome: GI condition outcomes (C. diff, AAD, H. pylori)
效果: None
None
研究人群: Adults with GI conditions
Key Statistics
6
研究数量
3000
受试者
↑
Positive
B
等级
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 次引用
Advances in experimental …
2024
2 次引用
Cureus
2023
5 次引用
Advances in experimental …
2019
17 次引用
Frontiers in medicine
2018
450 次引用
Pharmacological research
2018
132 次引用
The American journal …
2018
46 次引用
World journal of …
2017
68 次引用
Journal of pediatric …
2016
233 次引用
Clinical and experimental …
2016
82 次引用
Open forum infectious …
2016
58 次引用
Antibiotics (Basel, Switzerland)
2015
104 次引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 次引用
The American journal …
2012
104 次引用
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 次引用
Journal of clinical …
2011
432 次引用
Probiotics.
Review
American journal of …
2010
Current opinion in …
2009
82 次引用
The American journal …
2006
918 次引用
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 次引用
Medical science monitor …
2006
The American journal …
2001
648 次引用
International journal of …
2000
181 次引用
Clinical infectious diseases …
1998
346 次引用
Anaerobe
1997
40 次引用
Gastroenterology
1989
418 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
上限： Well-tolerated up to 1,000 mg/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 520 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | 228 |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
最佳服用时间： Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
已知相互作用
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 1,000 mg/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Saccharomyces boulardii help with Clostridioides difficile Infection (CDI)?
Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Clostridioides difficile Infection (CDI) management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Clostridioides difficile Infection (CDI)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Clostridioides difficile Infection (CDI)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.
Related Evidence
Saccharomyces boulardii 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。